Metabolic Disorders: Difference between revisions
Jump to navigation
Jump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
*[[Acid-beta-glucosidase]] | *[[Acid-beta-glucosidase]] | ||
*[[Molecular_playground/beta_2_microglobulin|ß-2 Microglobulin]] | *[[Molecular_playground/beta_2_microglobulin|ß-2 Microglobulin]] | ||
*[[HMG-CoA | *[[HMG-CoA Reductase]] | ||
*[[Molecular_Playground/Human_PPCA|Protective Protein/Cathepsin A (PPCA)]] | *[[Molecular_Playground/Human_PPCA|Protective Protein/Cathepsin A (PPCA)]] | ||
*[[Molecular_Playground/Human_Protective_Protein_Cathepsin_A|Protective Protein/Cathepsin A (PPCA) 2]] | *[[Molecular_Playground/Human_Protective_Protein_Cathepsin_A|Protective Protein/Cathepsin A (PPCA) 2]] | ||
Revision as of 20:29, 4 October 2010
Metabolic Disorders broadly covers illnesses related to faulty carbohydrate metabolism, amino acid metabolism, organic acid metabolism, or lysosomal storage.
Articles in Proteopedia concerning metabolic disorders include:
- Acid-beta-glucosidase
- ß-2 Microglobulin
- HMG-CoA Reductase
- Protective Protein/Cathepsin A (PPCA)
- Protective Protein/Cathepsin A (PPCA) 2
- Thiolase
- Treatment of Gaucher Disease
- Velaglucerase
- Velaglucerase Disulfide Connectivity
To view automatically seeded indices concerning Metabolic Disorderes See:
To view other Proteopedia pages about diseases & drug targets, See: Pharmaceutical Drug Targets